Navigation Links
Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Date:6/26/2012

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic cell transplants and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) cell transplantation, and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' immune tolerance based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based immune suppression would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of regulatory T cells among the CD 4 immune cells in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
2. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
3. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
4. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
5. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
6. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Moffitt researcher publishes book on nutritional management of cancer treatment effects
10. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
11. Moffitt Cancer Center researchers working at frontiers of melanoma research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2020)... ... April 02, 2020 , ... LifeLearn Animal Health , ... announced the launch of the veterinary CE course COVID-19: What we know and ... subscribers. , “When it comes to COVID-19, it’s important for practices and pet owners ...
(Date:4/1/2020)... ... April 02, 2020 , ... Medical Device Change Management, An FDAnews ... , What change management method should one be using for a medical ... on the type of change. Is it due to post-market design change, production process ...
(Date:4/1/2020)... ... April 01, 2020 , ... “Medical information ... California law,” says Keller Grover LLP attorney Eric A. Grover. “For that ... and the negligent release and disclosure of medical information can, under certain circumstances, ...
(Date:3/28/2020)... N.Y. (PRWEB) , ... March 27, 2020 , ... ... protect workers and the public from the spread of the coronavirus. Operating under ... crews are pressing forward with infrastructure renewal and environmental protection projects in the ...
(Date:3/27/2020)... ... March 27, 2020 , ... Justin ... NJ Top Docs. Dr. Kubeck has been approved every year consecutively since 2016. ... specializes in Spinal Surgery. , Dr. Kubeck’s medical education began at Thomas ...
Breaking Medicine News(10 mins):
(Date:4/5/2020)... Zug, Switzerland (PRWEB) , ... April 05, 2020 ... ... that has discovered and publicized the precise aetiology and pathology of COVID-19[1], we ... validation of our COVID-19 clinical predictions. , The SARS-CoV-2-mediated post-entry suppression of ...
(Date:4/2/2020)... ... ... NCPDP has elected its 2020-2021 Board of Trustees. The new Board members ... Wednesday, May 6, 2020. , Election Results – Newly Elected Board Members:, ... to the Board of Trustees. , Morgan Bojorquez, Director, Pharmacy Clinical Integration, ...
(Date:4/2/2020)... ... , ... Caitlin Richardson, a University of Washington MEDEX Physician ... Scholarship. , The $1,000 scholarship, awarded biannually to U.S. students who show ... the students pay tuition and other college-related expenses. , Rhonda Abbe, Director of ...
Breaking Medicine Technology: